Conference Details - Agenda
Ninth International Congress on the Future of Breast Cancer
Estancia La Jolla Hotel
La Jolla, CA
July 22-25, 2010
| 12:00 pm |
Registration
|
| 12:30 pm |
Welcome and Introductions
|
| 12:40 pm |
Keynote: Breast Cancer Steroid Receptor Targets
Ronald M. Evans |
| 1:05 pm |
Presession Survey
|
| 1:15 pm |
Breast Cancer Heterogeneity and Metastases
Joseph R. Nevins |
| 1:40 pm |
Tracking and Targeting Breast Cancer–Initiating Cells
Jeffrey M. Rosen |
| 2:05 pm |
Best of Breast Cancer Clinical Science: Highlights From 2009
Kathy Albain |
| 2:35 pm |
Panel Discussion
|
| 2:55 pm |
Break
|
| 3:15 pm |
Classification of Hormone Receptor–Positive Breast Cancer
Sunil Badve |
| 3:35 pm |
New Insights Into Optimizing Endocrine Therapy: Adjuvant
Stephen E. Jones |
| 3:55 pm |
New Insights Into Optimizing Endocrine Therapy: Metastatic
Stefan Glück |
| 4:15 pm |
Optimizing Premenopausal Adjuvant Endocrine Therapy: The First 5 Years
Jo Anne Zujewski |
| 4:35 pm |
Optimizing Premenopausal Adjuvant Endocrine Therapy: Endocrine Therapy for Life?
Frankie Ann Holmes |
| 4:55 pm |
Overcoming Endocrine Therapy Resistance: Views of a Basic Scientist
Suzanne A. W. Fuqua |
| 5:15 pm |
Overcoming Endocrine Therapy Resistance: Views of a Clinical Scientist
Douglas Yee |
| 5:35 pm |
Postsession Survey
|
| 5:45 pm |
Panel Discussion
|
| 6:05 pm |
Adjourn
|
| 7:00 pm-9:00 pm |
Welcome Reception
|
| 6:45 am |
Continental Breakfast
|
| 7:15 am |
Welcome and Introductions
|
| 7:20 am |
Presession Survey
|
| 7:25 am |
Molecular Determinants of Tumor Invasion and Metastases
Andrea Richardson |
| 7:50 am |
Are There Subtypes of HER2-Positive Breast Cancer?
Debu Tripathy |
| 8:10 am |
Is There an Optimal Adjuvant Therapy for HER2-Positive Breast Cancer?
Maureen Trudeau |
| 8:30 am |
Overcoming Trastuzumab Resistance: Views From a Basic Scientist
Carlos Arteaga |
| 8:50 am |
Overcoming Trastuzumab Resistance: Views From a Clinical Scientist
Edward Romond |
| 9:10 am |
Promising New Agents for HER2-Positive Breast Cancer
Joyce O’Shaughnessy |
| 9:30 am |
Panel Discussion
|
| 9:50 am |
Break
|
| 10:10 am |
Advancing the Impact of Angiogenesis Inhibitors: Views From a Basic Scientist
Robert Kerbel |
| 10:30 am |
Advancing the Impact of Angiogenesis Inhibitors: Views From a Clinical Scientist
Hope S. Rugo |
| 10:50 am |
Classifying Triple-Negative Breast Cancers
Charles Perou |
| 11:10 am |
Novel Therapies for Triple-Negative Breast Cancer
Joseph A. Sparano |
| 11:30 am |
Treating and Preventing Bone Metastases: Views From a Basic Scientist
Theresa A. Guise |
| 11:50 am |
Treating and Preventing Bone Metastases: Views From a Clinical Scientist
Julie R. Gralow |
| 12:10 pm |
Novel Cytotoxic Therapies
Hope S. Rugo |
| 12:30 pm |
Postsession Survey
|
| 12:40 pm |
Panel Discussion
|
| 1:00 pm |
Adjourn
|
| 2:30 pm-4:30 pm |
Workshop: Novel Therapeutic Agents (Non-CME Activity)
|
| 7:30 am |
Continental Breakfast
|
| 8:00 am |
Welcome and Introductions
|
| 8:05 am |
Obesity and Breast Cancer Outcomes
Rowan Chlebowski |
| 8:25 am |
Presession Survey
|
| 8:35 am |
The Role of Radiation Therapy in DCIS
Beryl McCormick |
| 8:55 am |
New Data Affecting Locoregional Management: Sentinel Lymph Node Biopsy and Genomic Profiling
Eleftherios Mamounas |
| 9:15 am |
New Insights Into the Prevention and Management of Familial Breast Cancer
David M. Euhus |
| 9:35 am |
Hypofractionated Breast Radiation Therapy
Beryl McCormick |
| 9:55 am |
Patient Preferences and Decision Analyses in Early Breast Cancer Treatment
Reshma Jagsi |
| 10:15 am |
Panel Discussion
|
| 10:35 am |
Break
|
| 10:55 am |
Is Chemotherapy Still Standard for Indolent Hormone Receptor–Positive/Node-Positive Breast Cancer?
|
| |
Green Light
Charles E. Geyer |
| |
Red Light
Kathy Albain |
| 11:25 am |
Should Adjuvant Platinum Be Used in High-Risk Triple-Negative Breast Cancer?
|
| |
Green Light
William M. Sikov |
| |
Red Light
Lori J. Goldstein |
| 11:55 am |
Postsession Survey
|
| 12:05 pm |
Panel Discussion
|
| 12:30 pm |
Adjourn
|
| 2:00 pm-4:00 pm |
Workshop: Novel Diagnostics (Non-CME Activity)
|
| 7:30 am |
Continental Breakfast
|
| 8:00 am |
Welcome and Introductions
|
| 8:10 am |
Oncology Consultations: Challenging Cases
|
| 9:10 am |
Tissue Factor and Breast Cancer
Janusz Rak |
| 9:30 am |
Targets in Circulating Tumor Cells
James M. Reuben |
| 9:50 am |
Break
|
| 10:10 am |
Pathways Underlying Aggressive Breast Cancers
Philippe Bedard |
| 10:30 am |
Genetic Polymorphisms Causing Resistance to Chemotherapy
Christine B. Ambrosone |
| 10:50 am |
Novel Combination Therapies With Promise for Metastatic Breast Cancer
Stacy Moulder |
| 11:10 am |
Panel Discussion
|
| 11:30 am |
Closing Comments
|
| 11:35 am |
Adjourn
|